Data +Oct 23, 2026
Positive data — MRNA Tanks as Positive Phase III Cancer Therapy Data Fails to Impress▸
high impact
ReadoutOct 20, 2026
Clinical data — Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Advances 2%▸
medium impact
Data +Oct 17, 2026
Positive data — Phase 3 Cancer Vaccine Success Could Change The Case For Moderna Stock▸
high impact
ReadoutOct 16, 2026
Clinical data — Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put▸
medium impact
Data +Oct 12, 2026
Positive data — Merck (MRK) Could Be 7% Below Fair Value On Phase III Cancer Vaccine Results▸
high impact
Data +Oct 11, 2026
Positive data — Moderna (MRNA) Is Up 18.4% After Cancer Vaccine Milestone And Nasdaq-100 Return Has The Bull Case Changed?▸
high impact
ReadoutOct 05, 2026
Clinical data — Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips▸
medium impact
EarningsJul 31, 2026
Q2 2026 report+2.6%muted
EarningsMay 01, 2026
Q1 2026 report+7.5%positive
EarningsFeb 13, 2026
FY 2025 report+17.7%positive
EarningsJan 12, 2026
FY 2025 report+16.3%positive
EarningsNov 06, 2025
Q3 2025 report+8.5%positive
EarningsAug 01, 2025
Q2 2025 report-3.2%negative
Data +Jul 10, 2025
mRNA-4157 Phase 3 interim (melanoma)▸
high impact
EarningsMay 01, 2025
Q1 2025 report-9.6%negative
EarningsFeb 14, 2025
FY 2024 report+2.2%muted
EarningsJan 13, 2025
FY 2024 report-4.0%negative
EarningsNov 07, 2024
Q3 2024 report-13.5%negative